- Home
- AMRN
as 03-28-2025 4:00pm EST
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.
| Founded: | 1989 | Country: | Ireland |
| Employees: | N/A | City: | DUBLIN 2 |
| Market Cap: | 189.2M | IPO Year: | 1993 |
| Target Price: | N/A | AVG Volume (30 days): | 2.2M |
| Analyst Decision: | Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.20 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.35 - $1.11 | Next Earning Date: | 03-12-2025 |
| Revenue: | $228,614,000 | Revenue Growth: | -25.51% |
| Revenue Growth (this year): | -24.76% | Revenue Growth (next year): | 19.11% |
Latest Amarin Corporation plc News
AMRN Breaking Stock News: Dive into AMRN Ticker-Specific Updates for Smart Investing
MT Newswires
10 days ago
Sector Update: Health Care Stocks Mixed Late Afternoon
MT Newswires
10 days ago
Amarin Shareholders Calls for Strategic Review
![New Research Exploring Mechanistic Benefits of Eicosapentaenoic Acid (EPA) In Vitro on Lipoprotein(a) [Lp(a)] Oxidation and on Protein Expression in Endothelial Cells in Combination with GLP-1 Receptor Agonist to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo](https://cdn.finquota.com/news/ea5eded0-8dd7-4eb4-895d-3c70a26d3bf0.jpg)
GlobeNewswire
10 days ago
New Research Exploring Mechanistic Benefits of Eicosapentaenoic Acid (EPA) In Vitro on Lipoprotein(a) [Lp(a)] Oxidation and on Protein Expression in Endothelial Cells in Combination with GLP-1 Receptor Agonist to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo
Zacks
16 days ago
AMRN's Q4 Earnings Lag Estimates, Stock Down on Ratio Change Plan
GuruFocus.com
16 days ago
Amarin Corp PLC (AMRN) Q4 2024 Earnings Call Highlights: Navigating Challenges and Expanding ...
Motley Fool
17 days ago
Amarin Plc (AMRN) Q4 2024 Earnings Call Transcript
MT Newswires
17 days ago
Amarin Plans 1-for-20 ADS Ratio Adjustment
Associated Press Finance
17 days ago
Amarin: Q4 Earnings Snapshot
Compare AMRN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AMRN Amarin Corporation plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.